Serum brain-derived neurotrophic factor levels and personality traits in patients with major depression

Nishimura, Hiroshi; Baba, Hajime; Satomura, Emi; Maeshima, Hitoshi; Takebayashi, Naoko; Namekawa, Yuki; Suzuki, Tomohiko; Arai, Heii

doi:10.1186/s12888-015-0413-1

Cited by 20 publications

(26 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study reported higher serum BDNF levels in MDD patients compared to HCs [17]. Another study found no significant alterations of serum BDNF levels between MDD patients and HCs [18]. Some studies reported no significant difference in serum BDNF levels before or after antidepressant therapy [19,20].…”

Section: Introductionmentioning

confidence: 99%

Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy

et al. 2020

View full text Add to dashboard Cite

Objective: We do not have any consistent markers for major depressive disorder (MDD) though various biological factors are involved in the pathophysiology. We aimed to evaluate the serum brain-derived neurotrophic factor (BDNF) levels in MDD patients with or without antidepressant therapy compared to healthy controls (HCs). Results:We assessed serum BDNF levels among three groups: drug-naïve MDD patients (n = 41), drug-treated MDD patients (n = 44), and age-and sex-matched HCs (n = 82). Serum BDNF levels were measured by enzyme-linked immunosorbent assay (ELISA) kit. Serum levels of BDNF were detected significantly lower in drug-naïve MDD patients compared to HCs. No significant alterations of serum BDNF levels between drug-treated patients and HCs were identified. Significant negative correlations between serum BDNF levels and Hamilton depression rating (Ham-D) scores were observed in both drug-naïve and drug-treated MDD patients. Receiver operating characteristic (ROC) analysis showed good diagnostic value for serum BDNF levels in drug-naïve MDD patients with the area under the curve at 0.821. The present study suggests that low serum BDNF levels may be involved in the pathophysiology of MDD. The reduced serum BDNF levels might be used as an early risk assessment marker for major depression.

show abstract

Section: Introductionmentioning

confidence: 99%

Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Reduced serum BDNF levels are associated with the increased risk for developing MDD: A case-control study with or without antidepressants therapy

Emon

Das

Nishuty

et al. 2020

Preprint

View full text Add to dashboard Cite

ObjectiveWe do not have any consistent markers for major depressive disorder (MDD) though various biological factors are involved in the pathophysiology. We aimed to evaluate the serum brain-derived neurotrophic factor (BDNF) levels in MDD patients with or without antidepressant therapy compared to healthy controls (HCs).ResultsWe assessed serum BDNF levels among three groups: drug-naïve MDD patients (n = 41), drug-treated MDD patients (n = 44), and age-and sex-matched HCs (n = 82). Serum BDNF levels were measured by enzyme-linked immunosorbent assay (ELISA) kit. Serum levels of BDNF were detected significantly lower in drug-naïve MDD patients compared to HCs. No significant alterations of serum BDNF levels between drug-treated patients and HCs were identified. Significant negative correlations between serum BDNF levels and Hamilton depression rating (Ham-D) scores were observed in both drug-naïve and drug-treated MDD patients. Receiver operating characteristic (ROC) analysis showed good diagnostic value for serum BDNF levels in drug-naïve MDD patients with the area under the curve at 0.821. The present study suggests that low serum BDNF levels may be involved in the pathophysiology of MDD. The reduced serum BDNF levels might be used as an early risk assessment marker for major depression.

show abstract

“…One study reported higher serum BDNF levels in MDD patients compared to HCs [17]. Another study found no signi cant alterations of serum BDNF levels between MDD patients and HCs [18]. Some studies reported no signi cant difference in serum BDNF levels before or after antidepressant therapy [19,20].…”

Section: Introductionmentioning

confidence: 99%

Reduced serum BDNF levels are associated with the increased risk for developing MDD: A case-control study with or without antidepressants therapy

Emon

Das

Nishuty

et al. 2019

Preprint

View full text Add to dashboard Cite

Objective We do not have any consistent markers for major depressive disorder (MDD) though various biological factors are involved in the pathophysiology. We aimed to evaluate the serum brain-derived neurotrophic factor (BDNF) levels in MDD patients with or without antidepressant therapy compared to healthy controls (HCs). Results We assessed serum BDNF levels among three groups: drug-naïve MDD patients (n = 41), drug-treated MDD patients (n = 44), and age-and sex-matched HCs (n = 82). Serum BDNF levels were measured by enzyme-linked immunosorbent assay (ELISA) kit. Serum levels of BDNF were detected significantly lower in drug-naïve MDD patients compared to HCs. No significant alterations of serum BDNF levels between drug-treated patients and HCs were identified. Significant negative correlations between serum BDNF levels and Hamilton depression rating (Ham-D) scores were observed in both drug-naïve and drug-treated MDD patients. Receiver operating characteristic (ROC) analysis showed good diagnostic value for serum BDNF levels in drug-naïve MDD patients with the area under the curve at 0.821. The present study suggests that low serum BDNF levels may be involved in the pathophysiology of MDD. The reduced serum BDNF levels might be used as an early risk assessment marker for major depression.

show abstract

Serum brain-derived neurotrophic factor levels and personality traits in patients with major depression

Cited by 20 publications

References 40 publications

Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy

Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy

Reduced serum BDNF levels are associated with the increased risk for developing MDD: A case-control study with or without antidepressants therapy

Reduced serum BDNF levels are associated with the increased risk for developing MDD: A case-control study with or without antidepressants therapy

Contact Info

Product

Resources

About